Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial - Tony S. K. Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, Hande Z. Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K. Laktionov, Igor Bondarenko, Karou Kubota, Gregory M. Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes - Dissemin

Language
Login

Published in

Elsevier, The Lancet

DOI: 10.1016/s0140-6736(18)32409-7

Links

Tools

Export citation

Search in Google Scholar

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Journal article published in 2019 by Tony S. K. Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M. Kowalski, Byoung Chul Cho, Hande Z. Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K. Laktionov, Igor Bondarenko, Karou Kubota, Gregory M. Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO